Real-time Estimate
Cboe BZX
02:21:33 2024-05-07 pm EDT
|
5-day change
|
1st Jan Change
|
25.96
USD
|
+0.06%
|
|
+4.98%
|
-16.26%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
2,134
|
3,391
|
3,224
|
2,707
|
4,433
|
3,855
|
-
|
-
|
Enterprise Value (EV)
1 |
2,003
|
3,231
|
3,089
|
2,863
|
4,993
|
4,409
|
4,511
|
4,665
|
P/E ratio
|
-7.93
x
|
-11.1
x
|
-7.02
x
|
-5.11
x
|
-5.8
x
|
-5.61
x
|
-6.62
x
|
-10.7
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
15.6
x
|
20.6
x
|
17.1
x
|
11
x
|
14.5
x
|
10.9
x
|
7.69
x
|
4.59
x
|
EV / Revenue
|
14.7
x
|
19.6
x
|
16.4
x
|
11.7
x
|
16.4
x
|
12.4
x
|
9
x
|
5.55
x
|
EV / EBITDA
|
-8.9
x
|
-12.9
x
|
-8.58
x
|
-6.4
x
|
-7.14
x
|
-6.44
x
|
-6.52
x
|
-14
x
|
EV / FCF
|
-6.84
x
|
-14.3
x
|
-8.34
x
|
-6.98
x
|
-9.09
x
|
-6.73
x
|
-7.27
x
|
-15
x
|
FCF Yield
|
-14.6%
|
-6.98%
|
-12%
|
-14.3%
|
-11%
|
-14.9%
|
-13.7%
|
-6.68%
|
Price to Book
|
8.18
x
|
12.4
x
|
6.82
x
|
30.8
x
|
-13.1
x
|
-19.6
x
|
-16.9
x
|
-15.6
x
|
Nbr of stocks (in thousands)
|
89,344
|
101,868
|
118,372
|
135,477
|
143,062
|
148,555
|
-
|
-
|
Reference price
2 |
23.88
|
33.29
|
27.24
|
19.98
|
30.99
|
25.95
|
25.95
|
25.95
|
Announcement Date
|
2/25/20
|
2/25/21
|
2/17/22
|
2/23/23
|
2/22/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
136.5
|
164.4
|
188.5
|
245.4
|
305.2
|
354.7
|
501.4
|
840.1
|
EBITDA
1 |
-225.1
|
-251.1
|
-359.8
|
-447
|
-699
|
-684.9
|
-692.2
|
-332.2
|
EBIT
1 |
-235.2
|
-265.2
|
-375.1
|
-457.3
|
-709.6
|
-675.2
|
-619.4
|
-368
|
Operating Margin
|
-172.38%
|
-161.32%
|
-199.03%
|
-186.39%
|
-232.51%
|
-190.36%
|
-123.55%
|
-43.81%
|
Earnings before Tax (EBT)
1 |
-253.6
|
-292.7
|
-436.4
|
-480.2
|
-747
|
-724.8
|
-689.7
|
-448.4
|
Net income
1 |
-254.3
|
-294.1
|
-434.7
|
-481.5
|
-749.6
|
-725.1
|
-674
|
-429.8
|
Net margin
|
-186.37%
|
-178.87%
|
-230.63%
|
-196.26%
|
-245.59%
|
-204.4%
|
-134.43%
|
-51.16%
|
EPS
2 |
-3.010
|
-3.010
|
-3.880
|
-3.910
|
-5.340
|
-4.626
|
-3.921
|
-2.433
|
Free Cash Flow
1 |
-292.9
|
-225.6
|
-370.6
|
-410.3
|
-549.5
|
-655.4
|
-620.2
|
-311.6
|
FCF margin
|
-214.64%
|
-137.21%
|
-196.64%
|
-167.23%
|
-180.05%
|
-184.76%
|
-123.71%
|
-37.1%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/25/20
|
2/25/21
|
2/17/22
|
2/23/23
|
2/22/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
46.76
|
56.12
|
53.11
|
65.22
|
67.73
|
59.3
|
65.21
|
77.23
|
79.07
|
83.69
|
78.76
|
88.37
|
91.36
|
94.27
|
-
|
EBITDA
|
-100.1
|
-95.43
|
-87.28
|
-86.1
|
-125.6
|
-148
|
-145.6
|
-233
|
-144.9
|
-175.5
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-103.6
|
-99.08
|
-89.83
|
-88.32
|
-127.7
|
-151.5
|
-148.2
|
-235.5
|
-147.7
|
-178.3
|
-172.3
|
-166.6
|
-163.1
|
-168.3
|
-
|
Operating Margin
|
-221.61%
|
-176.53%
|
-169.15%
|
-135.41%
|
-188.54%
|
-255.44%
|
-227.19%
|
-304.97%
|
-186.75%
|
-213.01%
|
-218.7%
|
-188.54%
|
-178.52%
|
-178.54%
|
-
|
Earnings before Tax (EBT)
1 |
-115.3
|
-113
|
-94.24
|
-95.14
|
-130.8
|
-160
|
-159.3
|
-244.3
|
-158.4
|
-185.1
|
-183.3
|
-181
|
-175.8
|
-180.3
|
-
|
Net income
1 |
-112.7
|
-113
|
-94.62
|
-95.64
|
-131.1
|
-160.1
|
-159.8
|
-244.8
|
-158.9
|
-186.1
|
-180.6
|
-176.9
|
-170.1
|
-185.7
|
-
|
Net margin
|
-241.06%
|
-201.3%
|
-178.17%
|
-146.65%
|
-193.63%
|
-270.02%
|
-244.98%
|
-316.99%
|
-201%
|
-222.31%
|
-229.25%
|
-200.16%
|
-186.15%
|
-196.97%
|
-
|
EPS
2 |
-0.9600
|
-0.9500
|
-0.8000
|
-0.8000
|
-1.090
|
-1.210
|
-1.170
|
-1.780
|
-1.110
|
-1.280
|
-1.241
|
-1.138
|
-1.085
|
-1.156
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
10/28/21
|
2/17/22
|
5/5/22
|
8/4/22
|
10/27/22
|
2/23/23
|
5/4/23
|
8/3/23
|
10/26/23
|
2/22/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
156
|
560
|
554
|
656
|
810
|
Net Cash position
1 |
130
|
161
|
135
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-0.3486
x
|
-0.8004
x
|
-0.8091
x
|
-0.9477
x
|
-2.437
x
|
Free Cash Flow
1 |
-293
|
-226
|
-371
|
-410
|
-550
|
-655
|
-620
|
-312
|
ROE (net income / shareholders' equity)
|
-108%
|
-109%
|
-127%
|
-193%
|
-
|
-
|
-609%
|
-44.2%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-42.6%
|
-33.2%
|
-50.2%
|
-60.2%
|
-69.8%
|
-43.5%
|
Assets
1 |
-
|
-
|
1,020
|
1,450
|
1,493
|
1,204
|
966
|
988.6
|
Book Value Per Share
2 |
2.920
|
2.680
|
3.990
|
0.6500
|
-2.360
|
-1.320
|
-1.530
|
-1.670
|
Cash Flow per Share
2 |
-
|
-2.250
|
-3.240
|
-3.250
|
-3.820
|
-3.620
|
-2.890
|
-
|
Capex
1 |
42.3
|
6.24
|
7.29
|
9.88
|
13.3
|
12.6
|
13.3
|
14
|
Capex / Sales
|
30.97%
|
3.8%
|
3.87%
|
4.03%
|
4.35%
|
3.56%
|
2.66%
|
1.67%
|
Announcement Date
|
2/25/20
|
2/25/21
|
2/17/22
|
2/23/23
|
2/22/24
|
-
|
-
|
-
|
Last Close Price
25.95
USD Average target price
44.07
USD Spread / Average Target +69.81% Consensus |
1st Jan change
|
Capi.
|
---|
| -16.26% | 3.86B | | +9.15% | 106B | | -1.08% | 104B | | +6.99% | 23.25B | | -11.55% | 22.5B | | -7.26% | 18.7B | | -37.08% | 17.95B | | -9.91% | 16.99B | | +7.55% | 14.26B | | +40.04% | 12.76B |
Bio Therapeutic Drugs
|